qchron.com /4 weeks ago

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ES...

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89;...

Read source
bioengineer.org /1 week ago

Immunotherapy Combined With Chemotherapy Extends Survival in Advanced SMARCA4-Deficient Lung Cancer

A real-world retrospective study demonstrates that adding first-line immunotherapy to chemotherapy significantly prolongs median overall survival by 23 months in advanced SMARCA4-d...

Read source
healio.com /2 weeks ago

Zanidatamab regimens improve survival for gastroesophageal cancer

First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...

Read source
qchron.com /4 weeks ago

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentati...

PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P

Read source
medicalxpress.com /1 week ago

Five-year survival from pediatric cancer rises to nearly 90% overall, but disparities by race and cancer type remain

Nearly nine in 10 young people with cancer were alive five years after diagnosis by 2017—up from six in 10 in 1975, according to the first comprehensive update of U.S. childhood ca...

Read source
bioengineer.org /1 week ago

Patient Survived Twenty Months After Small-Cell Transformation of Resected Lung Adenocarcinoma

A clinical case report documents a 48-year-old woman with EGFR-mutant lung adenocarcinoma who developed small-cell lung cancer transformation four years after surgery and survived...

Read source
bioengineer.org /1 week ago

Second-Line Trastuzumab Deruxtecan Yields 23-Month Progression-Free Survival in Gastroesophageal Cancer

A 63-year-old patient with HER2-positive metastatic gastroesophageal junction adenocarcinoma achieved 23 months of progression-free survival on second-line trastuzumab deruxtecan f...

Read source
drugs.com /3 weeks ago

Patients With Cancer Live Longer, Healthier When They Start Survivorship Care Before Or During Treatment

MONDAY, Oct. 26, 2026 — Starting survivorship care for patients with cancer before or during treatment can help them live longer and avoid cancer recurrence, a new study says.Surv...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.